110.00

0.99% 1.08

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $110.00, with a volume of 523.14K. It is up +0.99% in the last 24 hours and up +3.19% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Previous Close:

$108.92

Open:

$109.38

24h Volume:

523.14K

Relative Volume:

0.70

Market Cap:

$7.57B

Revenue:

$217.17M

Net Income/Loss:

$-202.68M

P/E Ratio:

-47.77

EPS:

-2.3028

Net Cash Flow:

$-156.63M

1W Performance:

-4.75%

1M Performance:

+3.19%

6M Performance:

+10.24%

1Y Performance:

+8.18%

1-Day Range:

$106.58

$112.59

1-Week Range:

$106.58

$118.31

52-Week Range:

$74.50

$122.20

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

414

Twitter

@rhythmpharma

Next Earnings Date

2026-08-04

Latest SEC Filings

RYTM's Discussions on Twitter

Compare RYTM vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RYTM Rhythm Pharmaceuticals Inc	110.00	7.50B	217.17M	-202.68M	-156.63M	-2.3028
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	RBC Capital Mkts	Outperform
Nov-25-25	Initiated	Citigroup	Buy
Nov-05-25	Downgrade	Oppenheimer	Outperform → Perform
Jul-10-25	Initiated	Goldman	Buy
Jul-07-25	Initiated	Leerink Partners	Outperform
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy
Mar-05-25	Resumed	Stifel	Buy
Jan-02-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Guggenheim	Buy
Sep-18-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	JMP Securities	Mkt Outperform
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

Aug 21, 2026

Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat

Aug 21, 2026

Aug 20, 2026

TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us

Aug 20, 2026

Aug 18, 2026

Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan

Aug 18, 2026

Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan

Aug 18, 2026

Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm

Aug 18, 2026

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm

Aug 18, 2026

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha

Aug 18, 2026

Rhythm Pharma files Form 3 for Chief Medical Officer Manher Joshi - Bitget

Aug 18, 2026

Aug 17, 2026

Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock - Investing.com

Aug 17, 2026

Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.com - Investing.com India

Aug 17, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares - MarketBeat

Aug 17, 2026

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock - MarketBeat

Aug 17, 2026

Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock By Investing.com - Investing.com Canada

Aug 17, 2026

Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock - Investing.com

Aug 17, 2026

Rhythm (NASDAQ: RYTM) CTO sells 5,079 shares in 10b5-1 plan - Stock Titan

Aug 17, 2026

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts - NewsBreak: Local News & Alerts

Aug 17, 2026

Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer - TradingView

Aug 17, 2026